InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort

Inclusion Criteria: * A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing Study participation * Men and women aged ≥ 25 - 80 (included) years of age * Hospitalized patients with one absolute lymphocyte count (ALC) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline * Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>2L per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., BIPAP), or patients intubated/ventilated for respiratory failure * Confirmed infection with COVID-19 by any acceptable test available/utilized at each site * Private insurance or government support (through NHS or other) Exclusion Criteria: * Pregnancy or breast feeding; * Refusal or inability to practice contraception regardless of the gender of the patient; * ALT and/or AST \> 5 x ULN * Known, active auto-immune disease; * Ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing; * Patients with past history of Solid Organ transplant. * Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load. * Patients whose respiratory condition is showing significant deterioration as indicated by: * requirement for a persistent and sustained increase in inspired oxygen concentrations of 20% or more over the past 24 hours to maintain SpO2 at greater than or equal to 88% (this 20 % limit does not apply to O2 delivered by nasal canula) * or need for invasive mechanical ventilation * Patients with chronic kidney dialysis * Patients showing an increase of the NEWS2 score by more than 6 points during the screening / baseline period (48 to 72 hrs prior to first administration) * Patients with a SOFA score ≥ 9 at baseline * Patients with a BMI \> 40 * Patients with baseline Rockwood Clinical Frailty Scale ≥ 6.(assessed as patient or proxy 4-week recall of chronic health and frailty status prior to COVID infection) * Patients under guardianship